Compare AstraZeneca plc (AZN) vs Seagate Technology Holdings PLC (STX) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

STX trades at $860.66, down 5.46% over 24 hours, with a bearish technical signal and elevated valuation ratios (P/E 81.66, P/S 17.61). Recent earnings beats (Q1 2026 EPS $4.10 vs. $3.51 expected) and strong revenue growth to $9.10B in 2025 highlight operational momentum, though negative shareholder equity and high debt pose balance sheet concerns. Analyst consensus remains bullish with a $987.86 price target, supported by AI-driven storage demand upgrades from Wells Fargo on July 10, 2026.

Outlook: STX benefits from AI infrastructure tailwinds and earnings consistency, but high leverage and volatile cash flows present risks. The stock offers upside to analyst targets if execution continues, yet investors face sensitivity to memory market cycles and debt servicing challenges amid competitive pressures.